Dimethyl fumarate inhibits ZNF217 and can be beneficial in a subset of estrogen receptor positive breast cancers

ConclusionThese data indicate that DMF ’s anti-breast cancer activities in the ER+HER2+models, at least in part, are due to inhibition of ZNF217. DMF is identified as a new covalent inhibitor of ZNF217.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research